# Anrotenib Plus Toripalimab Versus Toripalimab in Patients With Advanced Esophageal Squamous Cell Carcinoma

> **NCT04229849** · PHASE2 · UNKNOWN · sponsor: **Henan Cancer Hospital** · enrollment: 164 (estimated)

## Conditions studied

- Esophageal Squamous Cell Carcinoma

## Interventions

- **DRUG:** Anrotenib plus Toripalimab
- **DRUG:** Toripalimab

## Key facts

- **NCT ID:** NCT04229849
- **Lead sponsor:** Henan Cancer Hospital
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-01
- **Primary completion:** 2021-01
- **Final completion:** 2022-01
- **Target enrollment:** 164 (ESTIMATED)
- **Last updated:** 2020-01-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04229849

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04229849, "Anrotenib Plus Toripalimab Versus Toripalimab in Patients With Advanced Esophageal Squamous Cell Carcinoma". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT04229849. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*